![](https://www.webhealthnetwork.com/img/webhealth-logo.png)
Lymphoma, Large-cell - 75 Studies Found
Withdrawn |
: MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma : Lymphoma, Large-Cell : 2006-03-01 : Drug: MDX-060 |
Terminated |
: PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma : Lymphoma, Large-Cell, Diffuse : 2007-08-01 : Drug: PTK787 PTK787 - 1250mg p.o. daily. Initial dose of 750mg p.o daily starting on day 1 and increased |
Completed |
: A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma :
: Drug: brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion |
Completed |
: Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma : Large Cell Lymphoma : 2004-12-10 : Drug: SGN-30 |
Completed |
: Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma : Anaplastic Large-Cell Lymphoma : 2004-03-12 : Drug: SGN-30 (anti-CD30 mAb) |
Terminated |
: SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma : Anaplastic Large Cell Lymphoma : 2006-08-16 :
|
Withdrawn |
: A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib : Systemic Anaplastic Large-Cell Lymphoma : 2015-06-30 : Drug: crizotinib crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vinc |
Active, not recruiting |
: Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma : Anaplastic Large-cell Lymphoma : 2013-07-01 : Drug: brentuximab vedotin Brentuximab vedotin will be administered as a single intravenous (IV) infusion |
Recruiting |
: Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) :
: 2016-10-18 : Drug: Brentuximab Vedotin Brentuximab vedotin IV infusion. |
Terminated |
: Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma :
|